MODY Only Monogenic? A Narrative Review of the Novel Rare and Low-Penetrant Variants
- PMID: 39201476
- PMCID: PMC11354648
- DOI: 10.3390/ijms25168790
MODY Only Monogenic? A Narrative Review of the Novel Rare and Low-Penetrant Variants
Abstract
Maturity-onset diabetes of the young (MODY) represents the most frequent form of monogenic diabetes mellitus (DM), currently classified in 14 distinct subtypes according to single gene mutations involved in the differentiation and function of pancreatic β-cells. A significant proportion of MODY has unknown etiology, suggesting that the genetic landscape is still to be explored. Recently, novel potentially MODY-causal genes, involved in the differentiation and function of β-cells, have been identified, such as RFX6, NKX2.2, NKX6.1, WFS1, PCBD1, MTOR, TBC1D4, CACNA1E, MNX1, AKT2, NEUROG3, EIF2AK3, GLIS3, HADH, and PTF1A. Genetic and clinical features of MODY variants remain highly heterogeneous, with no direct genotype-phenotype correlation, especially in the low-penetrant subtypes. This is a narrative review of the literature aimed at describing the current state-of-the-art of the novel likely MODY-associated variants. For a deeper understanding of MODY complexity, we also report some related controversies concerning the etiological role of some of the well-known pathological genes and MODY inheritance pattern, as well as the rare association of MODY with autoimmune diabetes. Due to the limited data available, the assessment of MODY-related genes pathogenicity remains challenging, especially in the setting of rare and low-penetrant subtypes. In consideration of the crucial importance of an accurate diagnosis, prognosis and management of MODY, more studies are warranted to further investigate its genetic landscape and the genotype-phenotype correlation, as well as the pathogenetic contribution of the nongenetic modifiers in this cohort of patients.
Keywords: MODY; maturity-onset diabetes of the young; monogenic diabetes and diabetes mellitus.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Laver T.W., Wakeling M., Knox O., Colclough K., Wright C.F., Ellard S., Hattersley A.T., Weedon M.N., Patel K. Evaluation of Evidence for Pathogenicity Demonstrates That BLK, KLF11, and PAX4 Should Not Be Included in Diagnostic Testing for MODY. Diabetes. 2022;71:1128–1136. doi: 10.2337/db21-0844. - DOI - PMC - PubMed
-
- Tshivhase A., Matsha T., Raghubeer S. Diagnosis and Treatment of MODY: An Updated Mini Review. Appl. Sci. 2021;11:9436. doi: 10.3390/app11209436. - DOI
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous